Stay updated on Lenvatinib Pembrolizumab in Hepatobiliary Tumors Clinical Trial
Sign up to get notified when there's something new on the Lenvatinib Pembrolizumab in Hepatobiliary Tumors Clinical Trial page.

Latest updates to the Lenvatinib Pembrolizumab in Hepatobiliary Tumors Clinical Trial page
- Check2 days agoChange DetectedThe page has been updated to include information about the modernization of the ClinicalTrials.gov data ingest scheduled for June 2025, and the revision number has changed from v2.16.0 to v2.16.1.SummaryDifference1.0%
- Check10 days agoChange DetectedThe page has been updated to include a new version number (v2.16.0) and has removed a citation related to the KEYNOTE-224 trial.SummaryDifference3%
- Check17 days agoNo Change Detected
- Check24 days agoChange DetectedThe page has removed a citation regarding the genetic basis for clinical response to CTLA-4 blockade in melanoma, which included an erratum reference.SummaryDifference0.2%
- Check31 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2, indicating a revision in the content.SummaryDifference0.0%
- Check46 days agoChange DetectedThe web page has undergone significant changes, including the removal of detailed descriptions of a clinical study involving lenvatinib and pembrolizumab for advanced hepatobiliary tumors, while adding a new study on combinational immunotherapy for cholangiocarcinoma. The revision number has also been updated.SummaryDifference35%
- Check53 days agoChange DetectedThe web page has been updated from version 2.14.3 to version 2.14.4.SummaryDifference0.0%
Stay in the know with updates to Lenvatinib Pembrolizumab in Hepatobiliary Tumors Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Lenvatinib Pembrolizumab in Hepatobiliary Tumors Clinical Trial page.